Cantor Fitzgerald initiated coverage on Voyager Therapeutics
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/10/2025 | Overweight | Cantor Fitzgerald | |
12/2/2024 | $12.00 | Buy | Citigroup |
11/29/2024 | $7.00 → $11.00 | Outperform | Wedbush |
10/16/2024 | $15.00 | Outperform | Leerink Partners |
3/26/2024 | $22.00 | Buy | Guggenheim |
3/19/2024 | $30.00 | Buy | H.C. Wainwright |
3/7/2024 | $16.00 | Buy | Citigroup |
1/2/2024 | $14.00 | Equal Weight → Overweight | Wells Fargo |